Total Payments
$79,210
2024 Payments
$30,656
Companies
14
Transactions
100
Medicare Patients
9,558
Medicare Billing
$2.7M
Payment Breakdown by Category
Research$39,853 (50.3%)
Consulting$25,200 (31.8%)
Other$12,094 (15.3%)
Travel$1,508 (1.9%)
Food & Beverage$430.28 (0.5%)
Education$124.90 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39,853 | 51 | 50.3% |
| Consulting Fee | $25,200 | 12 | 31.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,094 | 22 | 15.3% |
| Travel and Lodging | $1,508 | 5 | 1.9% |
| Food and Beverage | $430.28 | 7 | 0.5% |
| Education | $124.90 | 3 | 0.2% |
Payments by Type
Research
$39,853
51 transactions
General
$39,357
49 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $26,327 | 54 | $0 (2024) |
| PFIZER INC. | $23,122 | 20 | $0 (2024) |
| Genentech, Inc. | $7,715 | 4 | $0 (2023) |
| Gilead Sciences, Inc. | $6,840 | 2 | $0 (2023) |
| Celgene Corporation | $6,295 | 4 | $0 (2018) |
| Seagen Inc. | $3,910 | 3 | $0 (2021) |
| Genmab U.S., Inc. | $2,238 | 2 | $0 (2023) |
| Acerta Pharma LLC | $1,043 | 2 | $0 (2018) |
| Seattle Genetics, Inc. | $900.00 | 1 | $0 (2019) |
| BTG International, Inc. | $661.35 | 3 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,656 | 44 | F. Hoffmann-La Roche AG ($15,642) |
| 2023 | $12,518 | 8 | F. Hoffmann-La Roche AG ($4,370) |
| 2022 | $3,061 | 4 | Gilead Sciences, Inc. ($3,020) |
| 2021 | $3,960 | 3 | Genentech, Inc. ($2,310) |
| 2020 | $6,225 | 4 | Genentech, Inc. ($3,300) |
| 2019 | $8,946 | 19 | F. Hoffmann-La Roche AG ($4,185) |
| 2018 | $6,370 | 7 | Celgene Corporation ($4,832) |
| 2017 | $7,473 | 11 | PFIZER INC. ($4,942) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,951.06 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $1,451.03 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $953.70 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $870.51 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $831.45 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $764.68 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $738.62 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $576.13 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $461.11 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $448.24 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $436.52 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $381.08 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $381.00 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.02 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.02 | Research |
| Study: AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $362.02 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $329.16 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $316.50 | Research |
| Study: Phase 1 EIH CD19 4 1BBL | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $119.17 | Research |
| Study: Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | ||||||
| 12/09/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/09/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/08/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 12/08/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 10/09/2024 | PFIZER INC. | ADCETRIS (Biological) | — | In-kind items and services | $1,400.00 | Research |
| Study: ADCETRIS CLINICAL PUBLICATION PROGRAM • Category: Oncology | ||||||
| 10/08/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | F. Hoffmann-La Roche AG | $8,088 | 17 |
| BRENTUXIMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,720 | 6 |
| AN OPEN-LABEL, MULTICENTER, PHASE I/II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF ESCALATING DOSES OF MOSUNETUZUMAB (BTCT4465A) AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKINS LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA | F. Hoffmann-La Roche AG | $7,237 | 12 |
| ADCETRIS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,160 | 5 |
| RV-FOL-GELARC-0683C - A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously Untreated Follicular Ly | Celgene Corporation | $3,308 | 1 |
| Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I/II Trial | F. Hoffmann-La Roche AG | $3,011 | 1 |
| CC-486-DLBCL-001 | Celgene Corporation | $1,463 | 1 |
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $1,082 | 1 |
| Glofitamab Plus R-CHOP has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated Large B-Cell Lymphoma Defined as High Risk by Circulating Tumor DNA: Preliminary Safety and Efficacy Results | F. Hoffmann-La Roche AG | $662.58 | 1 |
| PHASE III RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH INDOLENT NON-HODGKIN S LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY | F. Hoffmann-La Roche AG | $500.27 | 1 |
| CC-486-DLBCL-001 - (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND Advanced MDS | Celgene Corporation | $442.00 | 1 |
| Combining englumafusp alfa with glofitamab is safe and shows promising efficacy in patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma | F. Hoffmann-La Roche AG | $363.10 | 1 |
| Glofitamab (Glofit) Plus R-CHOP has a Favorable Safety Profile and Induces High Response Rates in Patients (Pts) with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined as High Risk by Circulating Tumor DNA (ctDNA): Preliminary Safety and Efficacy Results | F. Hoffmann-La Roche AG | $332.81 | 1 |
| Phase 1 EIH CD19 4 1BBL | F. Hoffmann-La Roche AG | $316.50 | 1 |
| an Open-Label, Multicenter, Phase IIB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | F. Hoffmann-La Roche AG | $165.42 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,375 | 23,173 | $2.5M | $522,897 |
| 2022 | 41 | 2,360 | 24,339 | $2.7M | $635,371 |
| 2021 | 43 | 2,488 | 32,407 | $3.2M | $852,846 |
| 2020 | 42 | 2,335 | 34,708 | $2.6M | $688,460 |
Total Patients
9,558
Total Services
114,627
Medicare Billing
$2.7M
Procedure Codes
169
All Medicare Procedures & Services
169 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 5,200 | $609,800 | $218,289 | 35.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 393 | 766 | $181,248 | $70,434 | 38.9% |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 18 | 1,230 | $221,400 | $47,078 | 21.3% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 17 | 1,550 | $240,250 | $35,858 | 14.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 168 | 341 | $202,458 | $33,608 | 16.6% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 23 | 420 | $485,100 | $32,295 | 6.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 200 | 276 | $41,676 | $17,698 | 42.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 371 | 809 | $26,689 | $6,796 | 25.5% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2023 | 21 | 382 | $66,468 | $5,718 | 8.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $16,856 | $5,462 | 32.4% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 18 | 42 | $38,418 | $5,242 | 13.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 59 | 101 | $27,977 | $4,947 | 17.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 91 | 209 | $42,427 | $4,701 | 11.1% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 29 | 29 | $24,476 | $3,878 | 15.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 114 | 287 | $40,896 | $3,459 | 8.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 65 | 157 | $29,830 | $3,449 | 11.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 23 | 23 | $8,004 | $3,123 | 39.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 45 | 50 | $11,250 | $2,465 | 21.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $10,728 | $2,272 | 21.2% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 18 | 49 | $12,233 | $2,098 | 17.1% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 15 | 613 | $13,486 | $1,984 | 14.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 27 | $8,613 | $1,540 | 17.9% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 35 | 35 | $1,223 | $1,170 | 95.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 35 | 35 | $1,084 | $1,047 | 96.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 64 | 1,030 | $62,830 | $848.42 | 1.4% |
About Dr. Nancy Bartlett, MD
Dr. Nancy Bartlett, MD is a Medical Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1316965759.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nancy Bartlett, MD has received a total of $79,210 in payments from pharmaceutical and medical device companies, with $30,656 received in 2024. These payments were reported across 100 transactions from 14 companies. The most common payment nature is "" ($39,853).
As a Medicare-enrolled provider, Bartlett has provided services to 9,558 Medicare beneficiaries, totaling 114,627 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 169 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Saint Louis, MO
- Active Since 07/17/2006
- Last Updated 04/15/2025
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1316965759
Products in Payments
- ADCETRIS (Biological) $16,790
- Non-Covered Product (Drug) $7,650
- Revlimid (Drug) $3,308
- Tecartus (Drug) $3,020
- Epkinly (Drug) $2,238
- Columvi (Biological) $2,090
- CC-486 (Drug) $1,905
- CC-122 (Drug) $1,082
- VORAXAZE (Drug) $661.35
- Ocrevus (Biological) $363.10
- Imbruvica (Drug) $99.00
- BELEODAQ (Drug) $25.90
- VENCLEXTA (Drug) $18.38
- VERZENIO (Drug) $15.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Saint Louis
Dr. Brad Kahl, Md, MD
Medical Oncology — Payments: $379,829
Medical Oncology $379,829
Dr. Russell Pachynski, Md, MD
Medical Oncology — Payments: $362,594
Medical Oncology $362,594
Dr. Mark Schroeder, Md, MD
Medical Oncology — Payments: $337,205
Medical Oncology $337,205
Dr. Ravi Vij, Md, MD
Medical Oncology — Payments: $262,216
Medical Oncology $262,216
Dr. Douglas Adkins, Md, MD
Medical Oncology — Payments: $166,184
Medical Oncology $166,184
Dr. Camille Abboud, Md, MD
Medical Oncology — Payments: $155,687
Medical Oncology $155,687